What is the difference between ALBUTEROL and SALMETEROL XINAFOATE?

ALBUTEROL and SALMETEROL XINAFOATE are both Beta-2 Agonist Bronchodilators, so they work through the same broad mechanism. They differ in dosing, half-life, side-effect frequency, and how individual patients tolerate them. See the head-to-head sections below for the specifics.

Is Albuterol the same as SEREVENT DISKUS?

No. Albuterol (ALBUTEROL) and SEREVENT DISKUS (SALMETEROL XINAFOATE) are distinct medications. They are sometimes confused because of similar branding or because they treat overlapping conditions, but they have different active ingredients and different safety profiles.

Which has fewer side effects, ALBUTEROL or SALMETEROL XINAFOATE?

Side-effect frequency varies by individual. The side-effect comparison section on this page shows FAERS-reported events for each drug side by side. FAERS is voluntary reporting, so it reflects what patients and clinicians chose to report, not absolute population risk.

Can I switch from ALBUTEROL to SALMETEROL XINAFOATE?

Switching medications should always be done under prescriber supervision. The "patient stories" section on this page includes accounts from people who have made the switch and what their transition felt like, but those are individual experiences, not protocols.

ALBUTEROL vs SALMETEROL XINAFOATE

Compare ALBUTEROL (Albuterol) and SALMETEROL XINAFOATE (SEREVENT DISKUS) — clinical data, side effects, and patient experiences.

ALBUTEROL

Albuterol, ProAir, Ventolin · Beta-2 Agonist Bronchodilator

How it works

Other agent

Approved for

INDICATIONS AND USAGE Albuterol tablets

USP are indicated for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease.

OralTablet

SALMETEROL XINAFOATE

SEREVENT DISKUS · Beta-2 Agonist Bronchodilator

How it works

12.1 Mechanism of Action Salmeterol is a selective LABA. In vitro studies show salmeterol to be at least 50 times more selective for beta 2 -adrenoceptors than albuterol. Although ...

Approved for

including patients with symptoms of nocturnal asthma. LABA

such as salmeterol

the active ingredient in SEREVENT DISKUS

appropriate steps must be taken to ensure adherence with both treatment components. If adherence cannot be assured

Oral, Respiratory (inhalation)Tablet

Quick Comparison

ALBUTEROLSALMETEROL XINAFOATE

Drug Class

Beta-2 Agonist Bronchodilator

Route

Oral

Oral, Respiratory (inhalation)

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

ALBUTEROL

Shortness of Breath

>10%

Drug Not Working

1-10%

Cough

1-10%

Fatigue

1-10%

Headache

1-10%

Nausea

1-10%

Diarrhea

0.1-1%

General Unwellness

0.1-1%

SALMETEROL XINAFOATE

Shortness of Breath

>10%

Drug Not Working

>10%

Cough

1-10%

Fatigue

1-10%

General Unwellness

1-10%

Headache

0.1-1%

Nausea

0.1-1%

Dizziness

0.1-1%

FDA Warnings

ALBUTEROL

WARNINGS Paradoxical Bronchospasm Albuterol tablets can produce paradoxical bronchospasm, which may be life threatening

SALMETEROL XINAFOATE

5 WARNINGS AND PRECAUTIONS • LABA as monotherapy (without ICS) for asthma increase the risk of asthma-related death and asthma-related hospitalizations
3 ) • Do not use in combination with an additional medicine containing a LABA because of risk of overdose
1 Asthma-Related Death LABA, such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without ICS) increase the risk of asthma-related death
When LABA are used in fixed - dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone

Clinical Trial Data

No head-to-head clinical studies found for ALBUTEROL vs SALMETEROL XINAFOATE.

ALBUTEROL vs SALMETEROL XINAFOATE: What You Should Know

Key Differences

Both ALBUTEROL and SALMETEROL XINAFOATE belong to the Beta-2 Agonist Bronchodilator class. While they share a similar mechanism of action, differences in pharmacokinetics, dosing, and side effect profiles may make one more suitable than the other for individual patients. ALBUTEROL is administered via Oral, whereas SALMETEROL XINAFOATE uses Oral or Respiratory (inhalation). Route of administration can affect onset of action and patient adherence.

Safety Considerations

ALBUTEROL carries 1 FDA warning. SALMETEROL XINAFOATE carries 4 FDA warnings. Patients should discuss all warnings and contraindications with their healthcare provider before starting or switching medications..

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.

Related Comparisons

ALBUTEROL vs FORMOTEROL FUMARATE→FORMOTEROL FUMARATE vs SALMETEROL XINAFOATE→ALBUTEROL vs LEVALBUTEROL HYDROCHLORIDE→ALBUTEROL vs FORMOTEROL FUMARATE DIHYDRATE→ALBUTEROL vs TIOTROPIUM BROMIDE AND OLODATEROL→ALBUTEROL vs FLUTICASONE PROPIONATE AND SALMETEROL→

Primary sources

Every figure on this comparison links back to its primary source. See data sources and methodology for the full provenance trail.

ALBUTEROL: DailyMed label · FAERS adverse events · ClinicalTrials.gov
SALMETEROL XINAFOATE: DailyMed label · FAERS adverse events · ClinicalTrials.gov

Loading comparison data...

ALBUTEROL vs SALMETEROL XINAFOATE

Compare ALBUTEROL (Albuterol) and SALMETEROL XINAFOATE (SEREVENT DISKUS) — clinical data, side effects, and patient experiences.

ALBUTEROL

Albuterol, ProAir, Ventolin · Beta-2 Agonist Bronchodilator

How it works

Other agent

Approved for

INDICATIONS AND USAGE Albuterol tablets

USP are indicated for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease.

OralTablet

SALMETEROL XINAFOATE

SEREVENT DISKUS · Beta-2 Agonist Bronchodilator

How it works

12.1 Mechanism of Action Salmeterol is a selective LABA. In vitro studies show salmeterol to be at least 50 times more selective for beta 2 -adrenoceptors than albuterol. Although ...

Approved for

including patients with symptoms of nocturnal asthma. LABA

such as salmeterol

the active ingredient in SEREVENT DISKUS

appropriate steps must be taken to ensure adherence with both treatment components. If adherence cannot be assured

Oral, Respiratory (inhalation)Tablet

Quick Comparison

ALBUTEROLSALMETEROL XINAFOATE

Drug Class

Beta-2 Agonist Bronchodilator

Route

Oral

Oral, Respiratory (inhalation)

Half-Life

—

FDA Approved

—

Side Effect Frequency Comparison

Estimated frequency (%) based on clinical trial data

Side Effects

ALBUTEROL

Shortness of Breath

>10%

Drug Not Working

1-10%

Cough

1-10%

Fatigue

1-10%

Headache

1-10%

Nausea

1-10%

Diarrhea

0.1-1%

General Unwellness

0.1-1%

SALMETEROL XINAFOATE

Shortness of Breath

>10%

Drug Not Working

>10%

Cough

1-10%

Fatigue

1-10%

General Unwellness

1-10%

Headache

0.1-1%

Nausea

0.1-1%

Dizziness

0.1-1%

FDA Warnings

ALBUTEROL

WARNINGS Paradoxical Bronchospasm Albuterol tablets can produce paradoxical bronchospasm, which may be life threatening

SALMETEROL XINAFOATE

5 WARNINGS AND PRECAUTIONS • LABA as monotherapy (without ICS) for asthma increase the risk of asthma-related death and asthma-related hospitalizations
3 ) • Do not use in combination with an additional medicine containing a LABA because of risk of overdose
1 Asthma-Related Death LABA, such as salmeterol, the active ingredient in SEREVENT DISKUS, as monotherapy (without ICS) increase the risk of asthma-related death
When LABA are used in fixed - dose combination with ICS, data from large clinical trials do not show a significant increase in the risk of serious asthma-related events (hospitalizations, intubations, death) compared with ICS alone

Clinical Trial Data

No head-to-head clinical studies found for ALBUTEROL vs SALMETEROL XINAFOATE.

ALBUTEROL vs SALMETEROL XINAFOATE: What You Should Know

Key Differences

Safety Considerations

This comparison is for informational purposes only. Always consult a qualified healthcare professional before making medication decisions.